Bilal Alqam
Cardiovascular Disease · Albuquerque, NMNPI 1982054250
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Medtronic at 45.3% of the total. 2025 is the largest year on record at $4,119, more than ten times the $121 reported in 2022.
Across 76 payments — averaging $109.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abiomed$1K
- Boston Scientific$709
- Abbott$678
- Novartis$504
- Amgen$418
- plus $1K from 10 others
What the payments were for
- Travel & lodging$3,64344%
- Food & beverage$4,13750%
- Education$5246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 33 | $3,766 |
| Abiomed | 5 | $1,039 |
| Boston Scientific | 8 | $709 |
| Abbott | 4 | $678 |
| Novartis | 7 | $504 |
| Amgen | 5 | $418 |
| Edwards Lifesciences | 2 | $265 |
| Novo Nordisk | 2 | $172 |
| Irhythm Technologies, Inc. | 1 | $127 |
| Bayer | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 2 | $120 |
| Johnson & Johnson | 1 | $120 |
| Alnylam Pharmaceuticals Inc. | 1 | $114 |
| Chiesi USA, Inc. | 2 | $88 |
| Heartflow, Inc. | 1 | $40 |
| Biosense Webster, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$944
- ENSITE$462
- WATCHMAN Access System$286
- LEQVIO$241
- Repatha$238
- SAPIEN 3 Ultra RESILIA$180
- CARDIOMEMS$129
- ZIO XT Patch$127
- WATCHMAN FLX$125
- AURORA EV-ICD MRI SURESCAN$123
- Adempas$121
- XARELTO$120
- ONPATTRO$114
How this compares
$8,305 in reported general payments places this provider in the 80th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $27,312 |
| JardianceEmpagliflozin | 17 | $17,936 |
| Metoprolol Succinate | 29 | $303 |
| Carvedilol | 26 | $272 |
| Lisinopril | 15 | $195 |
| Atorvastatin Calcium | 16 | $161 |
| Amlodipine Besylate | 15 | $130 |
| Furosemide | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- Carolina Ponce OrellanaAlbuquerque$12K
- Phillip CampAlbuquerque$11K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Daniel FriedmanAlbuquerque$6K
- Robert TaylorAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.